Pfizer lub cim tshiab ntawm qhov ncauj JAK1 inhibitor Cibinqo tau pom zoo hauv Nyij Pooj: nws txoj kev ua tau zoo yeej Dupixent!--2/2

Thaum lub Yim Hli xyoo no, Pfizer tau tshaj tawm cov txiaj ntsig zoo ntawm lub taub hau-rau-lub taub hau Phase 3 JADE DARE (B7451050) kev kawm. Txoj kev tshawb no tau ua nyob rau hauv cov neeg laus cov neeg laus uas muaj qhov nruab nrab mus rau qhov hnyav AD uas tau txais kev kho mob tom qab.abrocitinib(200 mg ntawm qhov ncauj, ib hnub ib zaug) tau ncaj qha piv nrog Dupixent (300 mg, txhaj tshuaj subcutaneously ib zaug txhua 2 lub lis piam). Hauv qhov kev tshawb fawb no,abrocitinibtau kho nrog 200 mg ntsiav tshuaj ntawm qhov ncauj ib hnub ib zaug, thiab Dupixent tau kho nrog 300 mg subcutaneous txhaj txhua txhua lub lis piam tom qab 600 mg induction koob. Txhua tus neeg mob tau txais kev kho mob keeb kwm yav dhau los.

Cov ntsiab lus tseem ceeb tshaj plaws ntawm txoj kev tshawb fawb no yog: (1) Qhov feem ntawm cov neeg mob uas ua tiav cov lus teb pruritic ntawm lub lim tiam thib ob ntawm kev kho mob, txhais tau tias yog qhov ntsuas peak pruritus tus lej ntsuas (PP-NRS, cov qhab nia ntau: 0-10) qhab nia. txhim kho ≥ 4 piv nrog cov hauv paus ntsiab lus (2) Qhov feem pua ​​​​ntawm cov neeg mob uas ua tiav thaj tsam eczema thiab qhov hnyav index-90 (EASI-90) cov lus teb ntawm 4 lub lis piam ntawm kev kho mob, txhais tau tias yog kev txhim kho ntawm EASI (cov qhab nia ntau: 0-72) tus qhab nia ntawm ≥90% piv nrog cov hauv paus. Cov ntsiab lus tseem ceeb thib ob yog qhov feem pua ​​​​ntawm cov neeg mob ua tiav cov lus teb EASI-90 ntawm lub lim tiam 16 ntawm kev kho mob. Txoj kev tshawb no yuav tso cai rau kev soj ntsuam ntawm txhua qhov sib txawv ntawm kev ua tau zoo uas yuav muaj nyob rau ntawm 6 lub hlis ntawm kev kho mob.

Cov txiaj ntsig tau pom tias txoj kev tshawb fawb tau mus txog qhov tseem ceeb ntawm qhov ua tau zoo kawg thiab qhov tseem ceeb thib ob qhov ua tau zoo kawg nkaus: Piv nrog Dupixent,abrocitinibmuaj kev txheeb xyuas zoo tshaj plaws hauv txhua qhov kev ntsuas kev ua tau zoo, thiab nws txoj kev nyab xeeb zoo ib yam nrog cov kev tshawb fawb yav dhau los. .

Dupixent tau koom ua ke tsim los ntawm Sanofi thiab Regeneron. Nws yog lub ntiaj teb' thawj zaug thiab tsuas yog tsom rau tus neeg sawv cev lom neeg tau pom zoo rau kev kho mob ntawm tus mob nruab nrab mus rau mob atopic dermatitis (AD), uas tuaj yeem txhim kho cov tawv nqaij ntawm cov neeg mob atopic dermatitis sai sai. Qib ntawm kev puas tsuaj thiab cov tsos mob ntawm khaus.

Dupixent tsom rau cov tsav tsheb tseem ceeb ntawm hom 2 mob. Cov tshuaj no yog ib tug tib neeg lub cev monoclonal antibody uas tshwj xeeb inhibits lub tshaj-kiv teeb liab ntawm ob lub ntsiab proteins, IL-4 thiab IL-13. IL-4 / IL-13 yog ob hom inflammatory yam, uas yog qhov tseem ceeb thiab lub hauv paus tsav tsheb ntawm cov kab mob hauv lub cev hauv hom 2 inflammatory kab mob. Hom 2 mob ua lub luag haujlwm tseem ceeb hauv cov kab mob xws li atopic dermatitis, mob hawb pob, mob rhinosinusitis nrog qhov ntswg polyps (CRSwNP), thiab eosinophilic esophagitis.

Dupixent tau tsim tawm thaum kawg ntawm Lub Peb Hlis 2017 thiab tau pom zoo los kho 3 hom kab mob uas tshwm sim los ntawm hom 2 mob: nruab nrab mus rau mob atopic dermatitis (cov neeg mob ≥ 6 xyoo), mob hawb pob rau mob hawb pob (cov neeg mob ≥ 12 xyoos), Mob rhinosinusitis nrog qhov ntswg polyps (CRSwNP, cov neeg laus).

Hauv Suav teb, thaum Lub Rau Hli 2020, Dupixent tau pom zoo los ntawm National Medical Products Administration (NMPA) rau kev kho mob ntawm tus mob nruab nrab mus rau mob atopic dermatitis (AD) rau cov neeg laus. Darbitux yog lub ntiaj teb no' thawj zaug thiab tsuas yog tsom rau tus neeg sawv cev lom neeg tau pom zoo rau kev kho mob ntawm tus mob atopic dermatitis hauv cov laus. Qib ntawm kev puas tsuaj thiab cov tsos mob ntawm khaus. Ua tsaug rau kev txhawb nqa kev tswj hwm kev tswj hwm tshuaj, Dabituo tau pom zoo hauv Suav teb ob xyoos ua ntej, muab cov neeg mob suav nrog cov kev kho mob tshiab.